Payment overview · 2025
General Payments
$3,588.32
140 reported records · 21 companies
Healthcare provider profile · identity verified
Michael D Kohen, M.D.
Allopathic & Osteopathic Physicians|Allergy & Immunology · DAYTONA BEACH, FL · NPI 1013909951
Verified facts
What the public records show
CMS Open Payments records show Michael D Kohen, M.D. received $3,588.32 in general payments during 2025 across 140 reported records.
UCB, Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Prolia, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OLUMIANT as an associated drug or biological on 560 records involving 277 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Olumiant by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $596.43 | 16.6% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $556.94 | 15.5% | 23 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $364.01 | 10.1% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $350.33 | 9.8% | 18 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $334.92 | 9.3% | 17 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $223.12 | 6.2% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $190.30 | 5.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $171.08 | 4.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $167.88 | 4.7% | 10 | 2025 |
| ADMA BioManufacturing LLC | Unresolved — no canonical attribution shown | $125.00 | 3.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $100.94 | 2.8% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $95.59 | 2.7% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $53.21 | 1.5% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $44.11 | 1.2% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $40.02 | 1.1% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $37.39 | 1.0% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $36.19 | 1.0% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $32.67 | 0.9% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $29.67 | 0.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.60 | 0.6% | 1 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $16.92 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,436.95 | 137 |
| Education | $151.37 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $569.18 | 21 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $365.11 | 13 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $364.01 | 10 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $320.21 | 16 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $259.40 | 13 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $223.12 | 4 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $190.30 | 6 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $171.08 | 9 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $142.55 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $137.20 | 7 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $100.94 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $77.91 | 5 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $53.21 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $52.97 | 3 | 2025 |
Source payment records
|
|||||
| CIBINQO Normalized: cibinqo |
Drug | PFIZER INC. | $49.38 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $46.73 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $44.11 | 2 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $40.03 | 2 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $40.02 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $36.19 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $32.67 | 1 | 2025 |
Source payment records
|
|||||
| JUBBONTI Normalized: jubbonti |
Biological | Sandoz Inc. | $29.67 | 2 | 2025 |
Source payment records
|
|||||
| Cimzia Normalized: cimzia |
Drug | UCB, Inc. | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $25.33 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $12.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PROLIA prolia |
2025 | Prolia | 2024 | 21 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | OLUMIANT open payments reported associated product |
CMS Open Payments — General Payments 560 supporting records · 277 recipient NPIs · example record 1186464669 |
Olumiant · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 565 | 179 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 526 | 167 |
| Prednisone | Prednisone | 488 | 169 |
| Leflunomide | Leflunomide | 264 | 77 |
| Montelukast Sodium | Montelukast Sodium | 227 | 74 |
| Allopurinol | Allopurinol | 207 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 61 |
| Ipratropium Bromide | Ipratropium Bromide | 147 | 54 |
| Sulfasalazine | Sulfasalazine | 129 | 53 |
| Folic Acid | Folic Acid | 88 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 30 |
| Risedronate Sodium | Risedronate Sodium | 86 | 33 |
| Azathioprine | Azathioprine | 80 | 27 |
| Leucovorin Calcium | Leucovorin Calcium | 77 | 25 |
| Gabapentin | Gabapentin | 71 | 24 |
| Xeljanz Xr | Tofacitinib Citrate | 61 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 57 | 16 |
| Cimzia (2 Pack) | Certolizumab Pegol | 52 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 52 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | 16 |
| Cevimeline Hcl | Cevimeline Hcl | 50 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 48 | 19 |
| Azelastine Hcl | Azelastine Hcl | 45 | 15 |
| Pilocarpine Hcl | Pilocarpine Hcl | 45 | 16 |
| Methylprednisolone | Methylprednisolone | 43 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 16 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 17 |
| Rinvoq | Upadacitinib | 34 | suppressed |
| Enbrel Mini | Etanercept | 32 | suppressed |
| Febuxostat | Febuxostat | 32 | 14 |
| Colchicine | Colchicine | 31 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 12 |
| Omeprazole | Omeprazole | 29 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 23 | suppressed |
| Olumiant | Baricitinib | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Enbrel | Etanercept | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 11 |
| Prolia | Denosumab | 21 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Epinephrine | Epinephrine | 19 | 19 |
| Amoxicillin | Amoxicillin | 17 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 17 | 11 |
| Mupirocin | Mupirocin | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Enbrel Sureclick | Etanercept | 14 | suppressed |
| Humira(Cf) Pen | Adalimumab | 14 | suppressed |
| Clarithromycin | Clarithromycin | 13 | 11 |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,588.32 · 140 records | UCB, Inc. | BENLYSTA, Bimzelx, Brinsupri, CIBINQO, COSENTYX, CUTAQUIG, CUVITRU, Cimzia, DUPIXENT, EVENITY, Grastek, Hizentra, JUBBONTI, KEVZARA, KRYSTEXXA, NEFFY, NUCALA, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, Odactra, PANZYGA, PROLIA, RINVOQ, Ragwitek, SKYRIZI, TALTZ, TAVNEOS, TEZSPIRE, TREMFYA, UPLIZNA, XELJANZ, Xembify, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Prolia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error